Research & Clinical Trials
Raffles Cancer Centre actively seeks partnerships with research organisations who share our passion in our mission to provide the best cancer care for our patients.
Clinical trials constitute an integral component of patient management at Raffles Hospital. Through these trials, our patients have access to novel therapeutic agents, which have yet to be made available in the market. These clinical trials give hope to patients whose conditions have failed to respond to standard lines of treatment.
Our oncologists and haematologists at Raffles Cancer Centre have abundant experience as principal investigators and co-investigators of well over 50 clinical trials in various phases (phase I, II, III), both investigator-initiated and pharmaceutical company-initiated, and as part of larger international multi-centre phase III trials.
Coordinated by the Hospital‘s Clinical Trial Unit, these trials help expand the treatment options available to patients.
All clinical trials involving humans are subjected to approval by the Hospital’s Institutional Review Board (IRB) which ensures all clinical trials are ethically acceptable and that the rights, safety and well-being of the patients are safeguarded at all times. The IRB also monitors the conduct of the clinical trials and ensures that they are in compliance with Good Clinical Practice on an ongoing basis.
|1||Lymphoma||Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND||Dr Dawn Mya||Recruiting|
|2||Lymphoma||An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed B-Cell Non-Hodgkin Lymphoma||Dr Dawn Mya||Recruiting|
|3||Acute Lymphoblastic Leukemia||Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Eligible for Hematopoietic Stem Cell Transplantation and who have Risk Factor(s) for Veno-Occlusive Disease.||Dr Yvonne Loh||Recruiting|
|4||Stem Cell Transplant||Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation||Dr Yvonne Loh||Recruiting|
|5||Breast Cancer||A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer ‑ RIGHTChoice Study||Dr Terence Tan||Recruiting|
|6||Lung Cancer||A Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer||Dr Terence Tan||Recruiting|
|7||Gastric Cancer||A Pilot Study of Natural Killer Group 2D (NKG2D) Ligand Expression in Cancer Cells of Patients with Advanced Gastric Cancer and Susceptibility to Cancer Cell Killing by Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells In Vitro.||Dr Terence Tan||Recruiting|
For more information, please contact:
Raffles Hospital Clinical Trials Unit
Mon - Fri: 9.00am to 5.00pm
Tel: +65 6311 2305
Your participation in this research study is purely voluntary. You may withdraw your participation at any phase during the study.
Updated on Nov 2019